文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝病:高危患者的识别与管理

Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

非酒精性脂肪性肝病(NAFLD)是全球肝病日益主要的原因,其进展亚型非酒精性脂肪性肝炎是肝移植的主要指征和肝细胞癌的重要原因。NAFLD总体患病率上升,模型预测越来越多患者将发展为晚期疾病,带来显著医疗负担。识别已存在纤维化或高风险进展为晚期肝病的患者对有效干预至关重要。本文提供识别NAFLD高危患者(非酒精性脂肪性肝炎伴晚期纤维化)的框架,并批判性评估当前可及的诊断和治疗方式。

要点

  • NAFLD患病率上升,模型预测越来越多患者将发展为晚期疾病。
  • 识别已存在纤维化或高风险进展为晚期肝病的患者至关重要。
  • 本文提供识别高危患者框架并评估当前诊断和治疗方式。

核心结论

  • 识别NAFLD患者中非酒精性脂肪性肝炎伴晚期纤维化的高危人群对有效干预和预防整体及肝脏相关疾病和死亡至关重要。

研究设计与样本

  • 本文为综述,提供识别NAFLD高危患者(非酒精性脂肪性肝炎伴晚期纤维化)的框架,并批判性评估当前可及的诊断和治疗方式。

主要发现

  • NAFLD是全球肝病日益主要的原因,非酒精性脂肪性肝炎是肝移植的主要指征和肝细胞癌的重要原因。
  • NAFLD总体患病率上升,模型预测越来越多NAFLD患者将发展为晚期疾病。
  • 晚期肝病患者增加将带来显著的医疗资源和成本负担。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) is an increasingly dominant cause of liver disease worldwide. The progressive subtype, nonalcoholic steatohepatitis, is a leading indication for liver transplantation and a noteworthy cause of hepatocellular carcinoma. The overall prevalence of NAFLD is on the rise, and even more concerning data modeling predicts that an increasing percentage of those with NAFLD will develop advanced disease. This increased volume of patients with advanced liver disease will impose a significant health care burden in terms of resources and cost. Thus, the identification of patients with established fibrosis or at high risk of developing advanced liver disease is critical to effectively intervene and prevent overall and liver-related morbidity and mortality. Herein, we provide a framework to consider for the identification of patients with NAFLD at high risk of nonalcoholic steatohepatitis with advanced fibrosis and provide a critical assessment of currently accessible diagnostic and treatment modalities.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Cheung A, Figueredo C, Rinella ME, et al. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol. 2019. PMID: 30839326. doi:10.14309/ajg.0000000000000058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。